BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Prostate
,
Laryngoscope
,
Doxorubicin
,
rs7903146
,
LEP
,
Coagulation
,
Breast Cancer
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
E545K
Summary
General Info
Curated Studies
Most Correlated Studies
Oncogenic PI3K mutations in cancer cells following growth factor deprivation
Explore Curated Studies Results
Literature
Most Relevant Literature
Unravelling the effect of the E545K mutation on PI3Kα kinase.
The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in …
Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA-E545K Mutation.
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Novel all-hydrocarbon stapled p110α[E545K] peptides as blockers of the oncogenic p110α[E545K]-IRS1 i…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Brea…
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
BKM120 in Cancers With PIK3CA Activating Mutations
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid T…
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ